ArticleBMC infectious diseases2025
Multi-omics driven biomarker discovery and pathological insights into Pseudomonas aeruginosa pneumonia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Label-free Raman spectroscopic imaging enables high-content molecular phenotyping of respiratory diseases from bronchoalveolar lavage fluid.Journal of translational medicine · 2026Article
- PAF Triggered Pyroptotic NETosis Aggravates Myocardial Ischemia/Reperfusion Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies.Archives of microbiology · 2026Review
- Screening and Targeting the HMGB1/RAGE Axis via Proteomics to Alleviate Inflammatory Responses in aJournal of inflammation research · 2026Article
- Airway microbiota and immunity associated with chronic obstructive pulmonary disease severity.Journal of translational medicine · 2025Article
- Metabolic Reprogramming in Respiratory Viral Infections: A Focus on SARS-CoV-2, Influenza, and Respiratory Syncytial Virus.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPseudomonas aeruginosa (P. aeruginosa) is a leading cause of hospital-acquired pneumonia, contributing significantly to morbidity and mortality, especially in immunocompromised patients. Understanding the molecular mechanisms underlying this infection is crucial for developing targeted therapeutic strategies. This study aims to elucidate the local and systemic pathways and biomarkers involved in the pathogenesis of P. aeruginosa pneumonia through an integrated multi-omics approach.
methodsWe performed a comprehensive proteomic and metabolomic analysis on clinical samples from patients diagnosed with P. aeruginosa pneumonia, including both bronchoalveolar lavage fluid (BALF) and serum to capture local and systemic host responses. Data were analyzed using advanced statistical techniques to identify differentially expressed proteins and metabolites. Pathway enrichment analysis was performed to highlight significant biological processes associated with the infection.
resultsOur findings revealed a significant upregulation of biomarkers associated with neutrophil extracellular traps (NETs) and oxidative stress, underscoring their pivotal roles in immune response and inflammatory pathology. Key proteins such as LCN2, CALR, and TPI1 were identified as central players in NET formation and oxidative stress pathways. Our integrated approach uniquely highlights the simultaneous local and systemic impact of NETs and oxidative stress. Additionally, by analyzing both BALF and serum, we observed distinct disruptions in metabolic pathways, particularly those related to amino acid metabolism and energy production, suggesting a bioenergetic crisis in response to infection. The combined analysis revealed key interactions between local and systemic immune responses, indicating a reprogramming of host energy pathways to meet the heightened immune demands, contributing to disease progression.
conclusionThis study provides a comprehensive understanding of the molecular mechanisms driving P. aeruginosa pneumonia by uniquely integrating BALF and serum analyses to explore both local and systemic host responses. Our findings highlight the dual role of NETs in both pathogen containment and tissue damage, as well as the metabolic reprogramming required to sustain immune activity. The identification of key biomarkers and disrupted pathways presents promising targets for therapeutic intervention, with the potential to refine diagnostic precision and improve patient outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.